Industry brand loyalty rates declined slightly in the first half of 2025 following last year's rebound, according to a new S&P Global Mobility analysis of new vehicle registration data through June. https://mma.prnewswire.com/media/2759582/Industry_Make_Loyalty_Trend_YTD_Through_June.jpg The industry's brand loyalty rate through June stood at 51.1%, down 1.4 percentage points (PPs) from the same period in 2024. The decrease […]

Artisight is the first Smart Hospital platform capable of autonomously documenting operating room activity into a patient's electronic health record (EHR) using advanced AI and computer vision. This eliminates the need for clinicians and other healthcare staff to manually document key milestones in an operating room procedure in addition to providing real-time updates that drive

Expanded Footprint, New Talent and Trial Success build great momentum With promising field trials and rapidly growing commercial acreage, Redox Bio-Nutrients today announced significant additions to its Midwest agronomy team. https://mma.prnewswire.com/media/2758305/Redox_Bio_Nutrients_Chad_John_and_Erica.jpg “We are excited about the extremely positive results we are seeing in this vital farming region,” said Redox President, Colton Moon. “With our products

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, today announced that the company will present at the H.C. Wainwright 27th Annual Global Investment Conference on Friday, September 5, 2025 at 7:00 a.m. ET. Zhenya Lindgardt, President and CEO,

(NASDAQ:IMNN), LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing on The Nasdaq Capital Market following confirmation from the Nasdaq Hearings Panel. As a

(NasdaqGM:CADL), NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci, Candel's President and Chief Executive Officer, will participate in upcoming investor conferences with

FRANKLIN, Ky., Aug. 28, 2025 (GLOBE NEWSWIRE) — On Saturday, August 30th, Kentucky Downs will host one of the nation's highest-stakes racing events, as the $3.5 million Grade 3 “Nashville Derby” takes center stage during a nationally televised NBC broadcast from 4:00 to 6:00 p.m. ET. Though the race is run at Kentucky Downs, its

IMUNON Successfully Regains Compliance with Nasdaq Minimum Bid Price Listing Requirement GlobeNewswire August 28, 2025 LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) — IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the minimum bid price requirement for continued listing

Candel Therapeutics to Participate in Upcoming Investor Conferences in September GlobeNewswire August 28, 2025 NEEDHAM, Mass., Aug. 28, 2025 (GLOBE NEWSWIRE) — Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical-stage biopharmaceutical company focused on developing multimodal biological immunotherapies to help patients fight cancer, announced today that Paul Peter Tak, M.D., Ph.D., FMedSci,

A securities fraud class action lawsuit styled Johnston v. LifeMD, Inc., et al., No. 1:25-cv-04761 (E.D.N.Y) has been filed and seeks to represent LifeMD (NASDAQ: LFMD) investors who purchased or otherwise acquired LifeMD securities between May 7, 2025 and August 5, 2025. https://mma.prnewswire.com/media/2590203/Hagens_Berman_Sobol_Shapiro_LLP_Logo.jpg The lawsuit comes after LifeMD reported disappointing Q2 2025 financial results and